Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Granted Continued Listing on Nasdaq as It Works Towards Meeting Requirements

NEW YORK(GenomeWeb) – BG Medicine said today that it has been granted continued listing on the Nasdaq Capital Market while it works towards compliance with exchange listing requirements.

In November, the company was told that it did not meet the minimum of $2.5 million in stockholders' equity or a market capitalization of at least $35 million required for listing, putting the company at risk of being delisted.

The company had until Jan. 4, 2015 to submit a plan to regain compliance with the listing rule. Today's announcement signals that Nasdaq has accepted this plan, giving BG Medicine until May 19, 2015 to regain compliance.

For the period ended Sept. 30, 2014, BG Medicine reported stockholders' equity of $1.7 million.

The company is also in danger of being delisted from Nasdaq for not being in compliance with a listing requirement calling for a minimum $1 closing bid price on its stock. BG Medicine will regain compliance on this front if the closing bid price of its stock is at or above $1.00 for a minimum of 10 consecutive business days by March 4, 2015.

The company's stock closed above the $1.00 threshold for the first time this year on Jan. 29 and has remained above $1.00 since then.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.